PIPELINE
What we develop
We expect to submit INDs for all our anti-AD vaccines by 2023
It took almost 20 years for the Nuravax team to develop and characterize its 3rd generation platform and develop multiple vaccines for people at risk of Alzheimer’s disease, tauopathies, Parkinson’s disease and α-synucleopathies using mostly NIA and NINDS R21s, R01s, and U01 awards. Based on positive data, NIA leadership recently supported the development of a SARS-CoV-2 MultiTEP-based vaccine for the elderly.
Current Status of IND / pre-IND products (vaccines)
1
2
3
4
CANDIDATE
DISCOVERY
PRE-CLINICAL STUDIES
SAFETY / TOXICOLOGY
IND
PHASE 1
PHASE 2
PHASE 3
AV-1959D
(Abeta DNA vaccine)
(Abeta DNA vaccine)
AV-1980R
(Tau Recom vaccine)
(Tau Recom vaccine)
AV-1959R
(Abeta Recom vaccine)
(Abeta Recom vaccine)
AV-1959R + 1980R (Dual vaccine)
Phase 1 ongoing
Protein vaccine
5
PV-1950
(Parkinson's disease)
(Parkinson's disease)
IND Clearance
Non-clinical trial results
Preventive vaccination of transgenic animals with Nuravax vaccines (beta-amyloid, tau) induced production of therapeutically potent titers of antibodies resulting in significantly less accumulation of beta-amyloid plaques and tau tangles, as well as oligomers, and reduced activation of microglia and astrocytes without increases in microhemorrhages.
Animal studies have shown that antibody levels in the blood were significantly higher than some other vaccines in clinical trials. We obtained an antibody titer higher than 1:250,000 in aged non-human primates with a long-lasting effect.
Animal studies have shown that antibody levels in the blood were significantly higher than some other vaccines in clinical trials. We obtained an antibody titer higher than 1:250,000 in aged non-human primates with a long-lasting effect.